CareDx (CDNA) to Release Earnings on Tuesday

CareDx (NASDAQ:CDNA) is expected to be issuing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $95.25 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.28). CareDx had a net margin of 17.97% and a return on equity of 18.03%. The business had revenue of $90.51 million during the quarter, compared to analysts’ expectations of $90.72 million. During the same quarter in the previous year, the company posted $0.25 EPS. The company’s revenue was down 6.1% compared to the same quarter last year. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Stock Performance

Shares of NASDAQ CDNA opened at $14.51 on Tuesday. The stock’s 50-day simple moving average is $14.13 and its 200-day simple moving average is $15.78. The firm has a market capitalization of $772.32 million, a PE ratio of 14.23 and a beta of 2.37. CareDx has a fifty-two week low of $10.96 and a fifty-two week high of $26.37.

Institutional Trading of CareDx

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. lifted its position in CareDx by 18.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after acquiring an additional 170,504 shares during the period. Raymond James Financial Inc. grew its position in CareDx by 7.6% in the 2nd quarter. Raymond James Financial Inc. now owns 180,619 shares of the company’s stock valued at $3,529,000 after buying an additional 12,742 shares during the last quarter. Meridiem Capital Partners LP purchased a new position in CareDx in the 2nd quarter valued at $2,411,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in CareDx by 11.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company’s stock valued at $2,378,000 after buying an additional 13,619 shares during the period. Finally, Sei Investments Co. raised its position in CareDx by 134.7% during the 2nd quarter. Sei Investments Co. now owns 112,493 shares of the company’s stock worth $2,199,000 after buying an additional 64,572 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CDNA. William Blair began coverage on shares of CareDx in a report on Tuesday, August 26th. They set a “market perform” rating on the stock. Craig Hallum reduced their price target on shares of CareDx from $40.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, July 18th. BTIG Research reaffirmed a “buy” rating and set a $22.00 price objective on shares of CareDx in a report on Tuesday, September 23rd. Zacks Research downgraded CareDx from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of CareDx in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, CareDx currently has an average rating of “Hold” and a consensus price target of $25.50.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.